VivoSeq
Hematology

Transfusion-Dependent Alpha-Thalassemia

3

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Transfusion-dependent Alpha-Thalassemia is an early-stage landscape with 3 programs across 1 company. The most active players are Agios Pharmaceuticals, Inc.. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Agios Pharmaceuticals, Inc.

3 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Not yet recruiting1 · 50%
Active, not recruiting1 · 50%

Clinical Trials

Trial Activity

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Subjects With α- or β- Transfusion-Dependent Thalassemia
Not yet recruiting·AAgios Pharmaceuticals, Inc.·Phase 3·NCT07506863·54 enrolled
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)
Active, not recruiting·AAgios Pharmaceuticals, Inc.·Phase 3·NCT04770779·258 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)